Clinicopathological features and EGFR gene mutation status in elderly patients with resected non–small-cell lung cancer
Teppei Nishii(Kanagawa Cancer Center), Munetaka Masuda(Uji Hospital), Tetsuya Isaka(Kanagawa Cancer Center), Tomoyuki Yokose(Kanagawa Prefectural Hospital Organization), Haruhiro Saito(Kanagawa Cancer Center), Tetsuro Kondo(Kanagawa Prefectural Hospital Organization), Hiroyuki Ito(Kanagawa Prefectural Hospital Organization), Masahiro Tsuboi(National Cancer Center Hospital East), Yataro Daigo(The University of Tokyo), Fumihiro Oshita(Kanagawa Cancer Center), Shoichi Matsukuma(Kanagawa Cancer Center), Kentaro Imai(Merck & Co., Inc., Rahway, NJ, USA (United States)), Haruhiko Nakayama, Kouzo Yamada(Kanagawa Cancer Center), Yohei Miyagi(Kanagawa Cancer Center), Shuji Murakami(Kanagawa Cancer Center)
Cited by 28
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
|The Lancet|2022|1.6k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k